Relay Therapeutics, Inc.

NasdaqGM:RLAY Stock Report

Market Cap: US$749.9m

Relay Therapeutics Management

Management criteria checks 2/4

Relay Therapeutics' CEO is Sanjiv Patel, appointed in Mar 2017, has a tenure of 7.83 years. total yearly compensation is $19.77M, comprised of 3.4% salary and 96.6% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth $3.99M. The average tenure of the management team and the board of directors is 6.8 years and 5.4 years respectively.

Key information

Sanjiv Patel

Chief executive officer

US$19.8m

Total compensation

CEO salary percentage3.4%
CEO tenure7.8yrs
CEO ownership0.5%
Management average tenure6.8yrs
Board average tenure5.4yrs

Recent management updates

Recent updates

We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

Dec 19
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

Relay Therapeutics Has Interesting Science That Needs To Be Proven In Trials

Dec 01

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Sep 11

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Aug 03
Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Apr 17
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Relay Therapeutics: Platform More Important Than Programs

Mar 13

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Feb 13

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 21
Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Nov 14
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Jun 08
Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Feb 22
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Oct 23
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts

Sep 30

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Sep 18

Why did Relay Therapeutics stock drop today?

Sep 09

Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 02
Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

CEO Compensation Analysis

How has Sanjiv Patel's remuneration changed compared to Relay Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$345m

Jun 30 2024n/an/a

-US$323m

Mar 31 2024n/an/a

-US$329m

Dec 31 2023US$20mUS$674k

-US$342m

Sep 30 2023n/an/a

-US$326m

Jun 30 2023n/an/a

-US$344m

Mar 31 2023n/an/a

-US$323m

Dec 31 2022US$8mUS$642k

-US$291m

Sep 30 2022n/an/a

-US$290m

Jun 30 2022n/an/a

-US$267m

Mar 31 2022n/an/a

-US$384m

Dec 31 2021US$9mUS$603k

-US$364m

Sep 30 2021n/an/a

-US$261m

Jun 30 2021n/an/a

-US$414m

Mar 31 2021n/an/a

-US$247m

Dec 31 2020US$4mUS$585k

-US$230m

Sep 30 2020n/an/a

-US$289m

Jun 30 2020n/an/a

-US$95m

Mar 31 2020n/an/a

-US$86m

Dec 31 2019US$4mUS$585k

-US$75m

Compensation vs Market: Sanjiv's total compensation ($USD19.77M) is above average for companies of similar size in the US market ($USD3.22M).

Compensation vs Earnings: Sanjiv's compensation has increased whilst the company is unprofitable.

CEO

Sanjiv Patel (50 yo)

7.8yrs

Tenure

US$19,770,838

Compensation

Dr. Sanjiv K. Patel, M.A., M.D., M.B.A., MBBS, had been an Independent Director at Prothena Corporation plc since May 18, 2021 until July 1, 2023. He serves as Independent Director of ARYA Sciences Acquisi...

Leadership Team

NamePositionTenureCompensationOwnership
Alexis Borisy
Co-Founder & Independent Chairman9.8yrsUS$581.14k0.14%
$ 1.0m
Sanjiv Patel
CEO, President & Director7.8yrsUS$19.77m0.53%
$ 4.0m
Mark Murcko
Co-Founder & Directorno dataUS$548.64k0.60%
$ 4.5m
Thomas Catinazzo
Chief Financial Officer6.8yrsUS$5.22m0.0046%
$ 34.6k
Brian Adams
Chief Legal Officer & Secretary6.8yrsUS$4.51m0.026%
$ 198.3k
Peter Rahmer
Chief Corporate Development Officerno dataUS$6.78m0.011%
$ 86.1k
Donald Bergstrom
President of Research & Development6.8yrsUS$8.57m0.043%
$ 323.9k
Dorothee Kern
Founderno datano datano data
David Shaw
Founderno datano datano data
Matthew Jacobson
Founderno datano datano data
Jim Watters
Chief Scientific Officer1yrno datano data
Jeanne Gray
Chief People Officerno datano datano data

6.8yrs

Average Tenure

52yo

Average Age

Experienced Management: RLAY's management team is seasoned and experienced (6.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alexis Borisy
Co-Founder & Independent Chairman9.8yrsUS$581.14k0.14%
$ 1.0m
Sanjiv Patel
CEO, President & Director7.8yrsUS$19.77m0.53%
$ 4.0m
Mark Murcko
Co-Founder & Director8.5yrsUS$548.64k0.60%
$ 4.5m
Douglas Ingram
Independent Director5.6yrsUS$548.64k0.015%
$ 112.0k
Linda Hill
Independent Director6.3yrsUS$551.14k0%
$ 0
George Demetri
Member of Oncology Advisory Board4.8yrsno datano data
Laura Shawver
Independent Director7.8yrsUS$551.14k0.024%
$ 179.2k
Lillian Siu
Member of Oncology Advisory Board4.8yrsno datano data
Jamilu Rubin
Independent Director5.3yrsUS$558.64k0.040%
$ 301.2k
Pamela Munster
Member of Oncology Advisory Board4.8yrsno datano data
Trever Bivona
Member of Oncology Advisory Board4.8yrsno datano data
Dejan Juric
Member of Oncology Advisory Board4.8yrsno datano data

5.4yrs

Average Tenure

62.5yo

Average Age

Experienced Board: RLAY's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 06:48
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Relay Therapeutics, Inc. is covered by 16 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Gaurav GoparajuBerenberg
Jason Matthew GerberryBofA Global Research